1. Home
  2. IMNM vs FRSX Comparison

IMNM vs FRSX Comparison

Compare IMNM & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$24.87

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Foresight Autonomous Holdings Ltd.

FRSX

Foresight Autonomous Holdings Ltd.

HOLD

Current Price

$1.07

Market Cap

5.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
FRSX
Founded
2006
N/A
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
5.0M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
IMNM
FRSX
Price
$24.87
$1.07
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$32.80
N/A
AVG Volume (30 Days)
951.9K
32.4K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,127.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.93
$0.78
52 Week High
$30.06
$3.00

Technical Indicators

Market Signals
Indicator
IMNM
FRSX
Relative Strength Index (RSI) 42.00 36.43
Support Level $19.28 $1.06
Resistance Level $27.14 $1.14
Average True Range (ATR) 1.08 0.09
MACD -0.48 0.00
Stochastic Oscillator 1.54 10.00

Price Performance

Historical Comparison
IMNM
FRSX

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.

Share on Social Networks: